Investors
A MESSAGE FROM OUR CEO
”Having extended patent protection until 2042 is pivotal for ensuring resomelagon’s value for us and future potential partners.”
-
May 28, 2025 Non RegulatoryInvitation to SynAct Pharma’s Capital Markets Day in Stockholm June 4
-
May 27, 2025 RegulatoryBulletin from the annual general meeting 2025 in SynAct Pharma AB
-
May 27, 2025 RegulatorySynAct Pharma publishes Q1 2025 interim results